Mechanisms for the clinical benefits of angiotensin II receptor blockers.
about
Critical Questions about PARADIGM-HF and the FutureSerum retinol-binding protein 4 levels are elevated but do not contribute to insulin resistance in newly diagnosed Chinese hypertensive patients.Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications.The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetesChronic static magnetic field exposure alters microvessel enlargement resulting from surgical intervention.3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial ProgrammeThe potential health benefits of taurine in cardiovascular diseaseAction on vascular risk factors: importance of blood pressure and lipid lowering in stroke secondary prevention.Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?Comparative assessment of angiotensin receptor blockers in different clinical settings.Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study.Therapeutic Implications of PPARgamma in Cardiovascular Diseases.Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade.The Relationship between Reactive Oxygen Species and Cardiac Fibrosis in the Dahl Salt-Sensitive Rat under ACEI AdministrationAnti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.Sardine peptide with angiotensin I-converting enzyme inhibitory activity improves glucose tolerance in stroke-prone spontaneously hypertensive rats.Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats.Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses.Comparative analysis of the effect of antihypertensive drugs on the survival of perforator flaps in a rat model.Nanomedical studies of the restoration of nitric oxide/peroxynitrite balance in dysfunctional endothelium by 1,25-dihydroxy vitamin D3 - clinical implications for cardiovascular diseases.Angiotensin II Receptor Blockers for the Treatment of Heart Failure: A Class Effect?
P2860
Q26741029-2A65467C-66EF-4AEB-8566-31E13E16681DQ33756947-6798474C-EB03-47D5-B8F2-0D70C59E2E4EQ33757082-C197047F-30E1-4989-ACBE-7DE7241150D5Q34135967-0CCA445A-B5C5-4C32-BE10-A3039481F818Q34625413-A285FC53-6325-41A5-A187-4FA44DD17391Q35669549-27B481EE-A205-4CBA-AC6D-F65CEF1A7D9AQ36242608-F7536087-644B-4107-A409-18D96A959031Q36726341-2EBD6982-0382-4BF9-A207-081A12B03DCBQ36855006-B8B9A024-9552-4897-AFD9-FA4FC9A979ADQ36981302-990A0B98-574D-4EC0-80AD-784BEDE41336Q36986398-EA275B79-2EBA-4923-B00D-5A2E09ABE968Q37078827-7E5910A5-4DFD-4E70-A77B-A418AFAA0187Q37362773-2CC44D52-F6A4-4963-B3CB-D6FC4DC4E9BBQ37649519-8EAFDD5B-0E65-4C65-9EAB-0380D4172BCCQ38391072-5AC123DD-23EF-4899-8296-4570136850F8Q38674739-FB70DF55-19B7-496F-8422-9381A000E837Q39217232-8051976B-A207-450A-AF98-2ADCB122B573Q41855435-56B21A13-3B5B-4231-8762-7C38622E4731Q42502118-0B56D0A3-2DE1-4076-BDC2-555FB546BFD7Q42539797-911D6512-31E4-47C9-A47E-62ACF1FA5400Q43107242-3DCD2D47-1D9F-48F6-9FE2-158E95856B96Q43195252-DE657270-8CE7-4ABA-AF1B-1D35317CD437Q43266133-F6378ED8-C3F8-477D-92CE-7432FCACA2D5Q45154756-AA5579BE-C5D6-418F-A1C1-1172DFE2567CQ45263919-CCD3AFC0-4A71-4F87-B216-46351608B6F2Q45736855-0B0C7AFF-E6E5-4920-A930-CB443DF19CF1Q46533109-B3FF087E-DC8B-4AD8-9F86-4BD60FCA271AQ48345763-D24890D0-21B5-480C-B929-664356126BC2Q49542207-076DA746-9FFC-44E5-BF3F-50651459D044Q57688960-4436A179-4F06-46FF-BF03-6E5CEFBFAC03
P2860
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@ast
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@en
type
label
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@ast
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@en
prefLabel
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@ast
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@en
P1476
Mechanisms for the clinical benefits of angiotensin II receptor blockers.
@en
P2093
Roland E Schmieder
P304
P356
10.1016/J.AMJHYPER.2004.11.032
P433
P577
2005-05-01T00:00:00Z